Leqembi (lecanemab) is a monoclonal antibody targeting aggregated forms of beta-amyloid, used for the treatment of Alzheimer's disease. This medication must be initiated during the mild cognitive impairment or mild dementia stage and requires strict medical monitoring. Due to its unique properties and mechanism of action, patients must pay special attention to relevant regulations when purchasing and using it.

How to Purchase Leqembi (Lecanemab)

Overseas Purchase

Patients may choose to consult and purchase Leqembi at hospital pharmacies or legitimate drugstores in countries or regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchasing and Using Leqembi (Lecanemab)

Genotyping Requirements

Prior to receiving treatment, patients should undergo ApoE ε4 genotyping.

Approximately 15% of Alzheimer's disease patients are homozygous for ApoE ε4, and these patients have a higher risk of developing ARIA (including symptomatic ARIA and ARIA with severe imaging findings).

Strict Monitoring Plan

Throughout the entire treatment course, patients need to undergo regular MRI scans.

A baseline MRI should be performed before initiating treatment.

MRI scans should be conducted within approximately one week before the 3rd, 5th, 7th, and 14th infusions.

If ARIA is detected on imaging, treatment recommendations will be determined based on the type, severity, and presence of symptoms.

Methods for Identifying the Authenticity of Leqembi (Lecanemab)

Verification of Drug Appearance Characteristics

Legitimate Leqembi should be a clear to opalescent, colorless to pale yellow solution.

Before use, the injectable drug product must be visually inspected for particulate matter and discoloration.

Inspection of Packaging Integrity

500 mg/5 mL: The packaging box contains one single-dose vial.

200 mg/2 mL: The packaging box contains one single-dose vial.

Confirmation of Storage Conditions

Unopened vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).

Verification of Ingredients

The active ingredient is lecanemab-irmb. Excipients include arginine hydrochloride, histidine, histidine hydrochloride monohydrate, polysorbate 80, and water for injection. The pH value is approximately 5.0.